Sebastian Zonte

Counsel, Los Angeles
sebastian.zonte@whitecase.com

Biography

Overview

Sebastian Zonte is a litigation counsel in the Intellectual Property Practice Group. His practice focuses on life sciences patent litigation. During law school, Sebastian served as a judicial extern in the Central District of California. Before law school, Sebastian worked as a medicinal chemist at Gilead Sciences.

Bars and Courts
California State Bar
US District Court for the Central District of California
New York
US District Court for the Southern District of New York
US Court of Appeals for the Federal Circuit
US Patent and Trademark Office
Education
JD
University of California, Los Angeles, School of Law
MS
Organic Chemistry
University of California, Berkeley
BS
Chemistry
University of Colorado
Languages
English
Romanian

Experience

Pharmaceuticals & Healthcare
Intellectual Property
Antitrust/Competition
  • Counsel to Myriad Genetics in patent infringement litigation brought against its PREQUEL™ brand prenatal screen.
  • Counsel to Pfizer in Hatch-Waxman litigations concerning the atopic dermatitis drug EUCRISA®.
  • Counsel to Vertex Pharmaceuticals in Hatch-Waxman litigations concerning the cystic fibrosis drug KALYDECO®.
  • Counsel to Pfizer in patent infringement and trade secret litigations concerning pneumococcal conjugate vaccines PREVNAR 13® and PREVNAR 20®.
  • Counsel to Pfizer in Federal Circuit appeal concerning protein-purification patents.
  • Counsel to Abiomed in patent litigation concerning Abiomed's IMPELLA® cardiac-support products.
  • Counsel to Pfizer in BPCIA proceedings concerning the biosimilar drugs ZIRABEV® (bevacizumab-bvzr) and RUXIENCE® (rituximab-pvvr).
  • Counsel to Pfizer in antitrust litigations concerning the drugs INFLECTRA® (infliximab-dyyb) and LIPITOR®.
  • Counsel to The Medicine Company in Hatch-Waxman litigations concerning the drug ANGIOMAX®*.
  • Counsel to Shire Pharmaceuticals in Hatch-Waxman litigations concerning the drug LIALDA®*.

*Matters prior to joining White & Case.

Publications

The US Supreme Court Fixes Constitutional Defect in the AIA by Making PTAB Decisions Reviewable by the USPTO Director (June 22, 2021)

The Supreme Court Hears Oral Argument in Arthrex (Mar. 3, 2021)

Federal Circuit Denies Rehearing of Decision Finding the Appointment of PTAB Judges Unconstitutional (Mar. 26, 2020)

Federal Circuit Rules the Appointment of PTAB Judges Unconstitutional – IPR Appellants May Get Another Shot with Remand to PTAB (Nov. 4, 2019)

Synthesis of 1'-C-Cyano Pyrimidine Nucleosides and Characterization as HCV Polymerase Inhibitors, 34 NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS 763 (2015)

Preparation and Biological Evaluation of 1'-cyano-2'-C-methylpyrimidine Nucleosides as HCV NS5B Polymerase Inhibitors, 24 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 3092 (2014)

Highly Potent HCV NS4B Inhibitors with Activity Against Multiple Genotypes, 57 JOURNAL OF MEDICINAL CHEMISTRY 2161 (2014)

Kevlar Functionalized Carbon Nanotubes for Next-Generation Composites, 22 CHEMISTRY OF MATERIALS 2164 (2010)

Site Isolation in Phosphorescent Bichromophoric Block Copolymers Designed for White Electroluminescence, 22 ADVANCED MATERIALS 77 (2010)

New Thermally Cross-Linkable Polymer and Its Application as a Hole-Transporting Layer for Solution Processed Multilayer Organic Light Emitting Diodes, 19 CHEMISTRY OF MATERIALS 4827 (2007)

U.S. Pat. No. 7,998,950, Antiviral Compounds

Related Content